

## **MEDIA STATEMENT**

PHILOGEN SPA ANNOUNCES PARTECIPATION IN “PEGS EUROPE - PROTEIN & ANTIBODY ENGINEERING SUMMIT”, 31 OCTOBER – 4 NOVEMBER 2016, LISBON, PORTUGAL

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “8<sup>th</sup> annual PEGS Europe – Protein & Antibody Engineering Summit” that will take place at the EPIC SANA Lisboa Hotel, from October 31 to November 4, 2016.

PEGS Europe is the largest European summit covering all the protein and antibody related topics and the five-day symposium will gather more than 800 attendees.

**Dr. Mattia Matasci**, who heads up cell line development activities at Philochem, will give a talk on “Targeted-Cytokines for the Treatment of Rheumatoid Arthritis”. The presentation is scheduled to take place on Tuesday, November 1<sup>st</sup>.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

### **About the Philogen group**

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit [www.philogen.com](http://www.philogen.com)

---